Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.42 |
| ▸ | RAD51 | Q06609 | 2/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.40 |
| ▸ | HTR3B | O95264 | 2/20 | 0.40 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CDC25A | P30304 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | CDC25C | P30307 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1147705 | 0.99 | MAOB (0.43) | MAOBKDM4EALDH1A1SMN1; SMN2HKDC1 | |
| Hydrochloric Acid SCHEMBL1147531 | 0.87 | TLR7 (0.45) | SMN1; SMN2RAD51HTR3EHTR3BHTR3A | |
| Hydrochloric Acid SCHEMBL1147720 | 0.85 | POLB (0.44) | KDM4EALDH1A1SMN1; SMN2RAD51HTR3E | |
| SCHEMBL1147798 | 0.84 | NPC1 (0.44) | KDM4ESMN1; SMN2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1147776 | 0.83 | SMN1; SMN2 (0.40) | SMN1; SMN2RAD51HTR3EHTR3BHTR3A | |
| Hydrochloric Acid SCHEMBL1147695 | 0.81 | OPRK1 (0.39) | MAOBKDM4EALDH1A1SMN1; SMN2HKDC1 | |
| Hydrochloric Acid SCHEMBL1147787 | 0.78 | HTR3E (0.44) | SMN1; SMN2RAD51HTR3EHTR3BHTR3A | |
| Hydrochloric Acid SCHEMBL1147803 | 0.78 | KDM4E (0.43) | KDM4EALDH1A1SMN1; SMN2RAD51HTR3E | |
| SCHEMBL1147833 | 0.74 | OPRK1 (0.47) | KDM4EALDH1A1HTR3EHTR3BHTR3A | |
| SCHEMBL4522606 | 0.74 | NPC1 (0.51) | MAOBKDM4EALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3700514-B1 | COMBINATION OF IL-8 INHIBITORS AND IL-6/GP-130 INHIBITORS FOR USE IN THE TREATMENT OF LUNG METASTASIS ASSOCIATED TO OSTEOSARCOMA | DOMPE FARM SPA (IT) | 2025-03-19 | — | — | EP | claimed |
| US-11999699-B2 | Substituted pyrazole amides | Grünenthal GmbH (DE) | 2024-06-04 | — | — | US | claimed |
| EP-4355733-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2024-04-24 | — | — | EP | claimed |
| EP-4277978-A1 | BLASTOCYST-LIKE CELL AGGREGATE AND METHODS | IMBA-Institut für Molekulare Biotechnologie GmbH (AT) | 2023-11-22 | — | — | EP | claimed |
| CN-116806258-A | Blastocyst-like cell aggregates and methods | IMBA-莫利库尔生物技术研究所 | 2023-09-26 | — | — | CN | claimed |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | GRUENENTHAL GMBH (DE) | 2023-01-26 | — | — | US | claimed |
| WO-2022263498-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2022-12-22 | — | — | WO | claimed |
| WO-2022152774-A1 | BLASTOCYST-LIKE CELL AGGREGATE AND METHODS | IMBA - INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH (AT) | 2022-07-21 | — | — | WO | claimed |
| US-20220054485-A1 | METHODS OF TREATING RIGHT VENTRICULAR FUNCTION IN PULMONARY HYPERTENSION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-02-24 | — | — | US | claimed |
| US-8058437-B2 | (Pyrroloquinoxalinyl) pyrazinecarbohydrazide-oxalic acid co-crystal for treatment of cancer and other diseases | NOVELIX PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | claimed |
| US-20110034473-A1 | NOVEL (PYRROLOQUINOXALINYL) PYRAZINECARBOHYDRAZIDE-OXALIC ACID CO-CRYSTAL FOR TREATMENT OF CANCER AND OTHER DISEASES | NOVELIX PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | US | claimed |
| EP-2276490-A1 | NOVEL (PYRROLOQUINOXALINYL) PYRAZINECARBOHYDRAZIDE-OXALIC ACID CO-CRYSTAL FOR TREATMENT OF CANCER AND OTHER DISEASES | Novelix Pharmaceuticals, Inc. (US) | 2011-01-26 | — | — | EP | claimed |
| WO-2009126743-A1 | NOVEL (PYRROLOQUINOXALINYL) PYRAZINECARBOHYDRAZIDE-OXALIC ACID CO-CRYSTAL FOR TREATMENT OF CANCER AND OTHER DISEASES | NOVELIX PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | claimed |
| EP-3845962-B1 | DISPLAY PANEL AND DISPLAY DEVICE COMPRISING SAME | SAMSUNG DISPLAY CO LTD (KR) | 2026-05-13 | — | — | EP | disclosed |
| US-20260092179-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF | OCTARINE BIO APS (DK) | 2026-04-02 | — | — | US | disclosed |
| US-12577238-B2 | Compositions and methods for modulating inflammatory and degenerative disorder | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2026-03-17 | — | — | US | disclosed |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-09 | — | — | US | disclosed |
| US-20060235034-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-10-19 | — | — | US | disclosed |
| US-20060142294-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142294-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | VEGFA, TEK, LIPG | MAOB 1741/4885KDM4E 3815/4885ALDH1A1 1365/4885 |
| US-11999699-B2 | Substituted pyrazole amides | SCN8A, SCN1A, SCN7A | MAOB 2124/4885KDM4E 2803/4885ALDH1A1 834/4885 |
| US-20110034473-A1 | NOVEL (PYRROLOQUINOXALINYL) PYRAZINECARBOHYDRAZIDE-OXALIC ACID CO-CRYSTAL FOR TREATMENT OF CANCER AND OTHER DISEASES | PDXK, OTC, XDH | MAOB 851/4885KDM4E 3090/4885ALDH1A1 1416/4885 |
| US-20260092179-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF | TDO2, BLVRB, INMT | MAOB 300/4885KDM4E 1143/4885ALDH1A1 1612/4885 |
| US-12577238-B2 | Compositions and methods for modulating inflammatory and degenerative disorder | TNF, TNFSF11, CD40 | MAOB 2892/4885KDM4E 4035/4885ALDH1A1 2788/4885 |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | VEGFA, TEK, MCL1 | MAOB 2037/4885KDM4E 3554/4885ALDH1A1 1558/4885 |
| US-20060235034-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | VEGFA, TEK, MCL1 | MAOB 2037/4885KDM4E 3554/4885ALDH1A1 1558/4885 |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | SCN8A, SCN1A, SCN7A | MAOB 2124/4885KDM4E 2803/4885ALDH1A1 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.